NRx subsidiary awarded $11.2M DARPA contract for depression trial

NRx Defense, a subsidiary of NRXP, entered into a prime contract with DARPA valued at $11.2 million ($6.7M initially obligated) to conduct a clinical trial of NRX-101 combined with transcranial magnetic stimulation for treatment-resistant depression over 18 months. This is concrete funding for an FDA-approved clinical program, but at ~2–3% of typical biotech market cap for development-stage companies, the near-term impact is moderate unless it signals regulatory confidence or de-risks the program materially."

NRXP's subsidiary won an $11.2 million government contract to run a clinical trial testing its depression drug combined with a brain stimulation device. The trial has FDA approval and will begin enrolling patients.